A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

被引：79

作者：

Best, O. G. ^{[1
]}

Gardiner, A. C. ^{[1
]}

Davis, Z. A. ^{[1
]}

Tracy, I. ^{[1
]}

Ibbotson, R. E. ^{[1
]}

Majid, A. ^{[2
]}

Dyer, M. J. S. ^{[3
]}

Oscier, D. G. ^{[1
]}

机构：

[1] Royal Bournemouth Hosp, Dept Mol Biol & Cytogenet, Bournemouth, Dorset, England

[2] Univ Leicester, Toxicol Unit, MRC, Leicester, Leics, England

[3] Univ Hosp, Dept Haematol, Leicester, Leics, England

来源：

LEUKEMIA | 2009年 / 23卷 / 01期

基金：

英国医学研究理事会;

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; MUTATIONAL STATUS;

D O I：

10.1038/leu.2008.260

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：212 / 214

页数：3

共 8 条

[1] Emerging therapy for chronic lymphocytic leukaemia [J].

Auer, Rebecca L. ;

Gribben, John ;

Cotter, Finbarr E. .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (05) :635-644

[2] A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL [J].

Best, O. G. ;

Gardiner, A. C. ;

Majid, A. ;

Walewska, R. ;

Austen, B. ;

Skowronska, A. ;

Ibbotson, R. ;

Stankovic, T. ;

Dyer, M. J. S. ;

Oscier, D. G. .

LEUKEMIA, 2008, 22 (07) :1456-1459

[3] Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial [J].

Catovsky, D. ;

Richards, S. ;

Matutes, E. ;

Oscier, D. ;

Dyer, M. J. S. ;

FBezares, R. ;

Pettitt, A. R. ;

Hamblin, T. ;

Milligan, D. W. ;

Child, J. A. ;

Hamilton, M. S. ;

Dearden, C. E. ;

Smith, A. G. ;

Bosanquet, A. G. ;

Davis, Z. ;

Brito-Babapulle, V. ;

Else, M. ;

Wade, R. ;

Hillmen, P. .

LANCET, 2007, 370 (9583) :230-239

[4]

DORHNER H, 2000, NEW ENGL J MED, V343, P1910

[5] Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status [J].

Mockridge, C. Ian ;

Potter, Kathleen N. ;

Wheatley, Isla ;

Neville, Louise A. ;

Packham, Graham ;

Stevenson, Freda K. .

BLOOD, 2007, 109 (10) :4424-4431

[6] Multivariate analysis of prognostic factors in CLL:: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors [J].

Oscier, DG ;

Gardiner, AC ;

Mould, SJ ;

Glide, S ;

Davis, ZA ;

Ibbotson, RE ;

Corcoran, MM ;

Chapman, RM ;

Thomas, PW ;

Copplestone, JA ;

Orchard, JA ;

Hamblin, TJ .

BLOOD, 2002, 100 (04) :1177-1184

[7] Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects [J].

Pettitt, A. R. ;

Matutes, E. ;

Oscier, D. .

LEUKEMIA, 2006, 20 (08) :1441-1445

[8]

Zenz T, 2007, BLOOD, V110, p615A

← 1 →